| Ruxolitinib |
115 |
25-oct-2026 |
conventional
|
| Ropeginterferon alfa-2b (Besremi) |
49 |
08-nov-2026 |
conventional
|
| Hydroxyurea |
44 |
01-nov-2026 |
conventional
|
| Pacritinib |
23 |
27-sep-2026 |
conventional
|
| Momelotinib |
21 |
11-oct-2026 |
conventional
|
| Phlebotomy-only maintenance in PV |
20 |
25-oct-2026 |
conventional
|
| INCA033989 (novel investigational agent for MPN) |
20 |
25-oct-2026 |
conventional
|
| Fedratinib |
19 |
11-oct-2026 |
conventional
|
| Selinexor + Ruxolitinib combination |
17 |
25-oct-2026 |
conventional
|
| ASTX727 (oral cedazuridine + decitabine) |
14 |
27-sep-2026 |
conventional
|
| Pre-transplant bridging (ruxolitinib) |
11 |
13-sep-2026 |
conventional
|
| Bomedemstat |
10 |
20-sep-2026 |
conventional
|
| Rusfertide (hepcidin mimetic) |
8 |
25-oct-2026 |
conventional
|
| Pelabresib (BET bromodomain inhibitor) |
8 |
25-oct-2026 |
conventional
|
| Fludarabine + Busulfan conditioning regimen |
8 |
20-sep-2026 |
conventional
|
| Navitoclax + Venetoclax + Decitabine combination |
8 |
13-sep-2026 |
conventional
|
| Azacitidine + Venetoclax + Gilteritinib combination |
7 |
27-sep-2026 |
conventional
|
| INCB057643 (BET bromodomain inhibitor) |
7 |
07-jun-2026 |
conventional
|
| ASTX727 + Venetoclax combination (CMML / MDS-MPN) |
6 |
27-sep-2026 |
conventional
|
| Peri-transplant ruxolitinib for GVHD prevention |
6 |
13-sep-2026 |
conventional
|
| Anagrelide |
6 |
13-sep-2026 |
conventional
|
| AJ1-11095 (Type II JAK2 inhibitor) |
6 |
13-sep-2026 |
conventional
|
| Elritercept (novel agent for myelofibrosis) |
5 |
25-oct-2026 |
conventional
|
| Azacitidine (5-AZA) |
4 |
04-oct-2026 |
conventional
|
| Luspatercept |
3 |
25-oct-2026 |
conventional
|
| Flonoltinib maleate |
3 |
13-sep-2026 |
conventional
|
| Itacitinib + Tacrolimus + Sirolimus (GVHD prophylaxis) |
3 |
28-jun-2026 |
conventional
|
| Navitoclax + Ruxolitinib combination |
2 |
25-oct-2026 |
conventional
|
| Mutant CALR peptide vaccine |
2 |
04-oct-2026 |
conventional
|
| Trametinib |
2 |
13-sep-2026 |
conventional
|
| Azacitidine + Ruxolitinib combination |
2 |
13-sep-2026 |
conventional
|
| TQ05105 (JAK2 inhibitor) |
2 |
07-jun-2026 |
conventional
|
| CPX-351 (liposomal daunorubicin + cytarabine) |
2 |
24-may-2026 |
conventional
|
| Gecacitinib hydrochloride (JAK/ACVR1 inhibitor) |
2 |
28-apr-2026 |
conventional
|
| Selcodebart |
1 |
25-oct-2026 |
conventional
|
| CALR-directed antibody-drug conjugates |
1 |
25-oct-2026 |
conventional
|
| RPG4 (CALR-directed CAR T-cell therapy) |
1 |
25-oct-2026 |
conventional
|
| CALR peptide vaccines |
1 |
25-oct-2026 |
conventional
|
| CALR-directed bispecific T-cell engagers |
1 |
25-oct-2026 |
conventional
|
| Epitranscriptomic (m6A) pathway inhibitors in MPN |
1 |
18-oct-2026 |
conventional
|
| AG-236 |
1 |
11-oct-2026 |
conventional
|
| Lustracept (MF-associated anemia) |
1 |
04-oct-2026 |
conventional
|
| Navtemadlin (MDM2 inhibitor) |
1 |
04-oct-2026 |
conventional
|
| Ascorbic acid plus combination chemotherapy (CMML/CCUS) |
1 |
04-oct-2026 |
alternative
|
| DMR-001 (mutant CALR-targeted antibody) |
1 |
04-oct-2026 |
conventional
|
| PIM kinase inhibitors (MPN) |
1 |
04-oct-2026 |
conventional
|
| Mutant CALR BiTEs and antibody-drug conjugates |
1 |
04-oct-2026 |
conventional
|
| Mutant CALR CAR-T cells |
1 |
04-oct-2026 |
conventional
|
| Mutant CALR-specific monoclonal antibodies |
1 |
04-oct-2026 |
conventional
|
| PRT12396 (mutant-selective JAK2V617F inhibitor) |
1 |
27-sep-2026 |
conventional
|
| Metronomic ASTX727 + Venetoclax (R/R AML, HR-MDS, HR/AP MPN) |
1 |
27-sep-2026 |
conventional
|
| Pitavastatin (antifibrotic in JAK2V617F MF) |
1 |
27-sep-2026 |
alternative
|
| Dasatinib |
1 |
27-sep-2026 |
conventional
|
| Asciminib |
1 |
27-sep-2026 |
conventional
|
| Deucravacitinib (TYK2 inhibitor in MPN) |
1 |
27-sep-2026 |
conventional
|
| Bezuclastinib (CGT9486) |
1 |
20-sep-2026 |
conventional
|
| Venetoclax + FLAMSA + Treosulfan conditioning (FLAMSAClax) |
1 |
20-sep-2026 |
conventional
|
| CLAG-M or FLAG-Ida + TBI reduced-intensity conditioning |
1 |
20-sep-2026 |
conventional
|
| RVU120 (investigational agent for MF) |
1 |
20-sep-2026 |
conventional
|
| Emavusertib |
1 |
20-sep-2026 |
conventional
|
| Canakinumab |
1 |
20-sep-2026 |
conventional
|
| Direct oral anticoagulants (DOACs) in MPN thrombosis |
1 |
20-sep-2026 |
conventional
|
| Aspirin in MPN |
1 |
20-sep-2026 |
conventional
|
| Azacitidine + Pacritinib (CMML) |
1 |
13-sep-2026 |
conventional
|
| LP-108 + Azacitidine combination |
1 |
13-sep-2026 |
conventional
|
| Clofarabine + Melphalan conditioning regimen |
1 |
13-sep-2026 |
conventional
|
| Trametinib + Azacitidine (JMML) |
1 |
13-sep-2026 |
conventional
|
| Reduced-intensity haploidentical HCT (myelofibrosis) |
1 |
13-sep-2026 |
conventional
|
| Axatilimab (CSF1R monoclonal antibody) |
1 |
13-sep-2026 |
conventional
|
| Decitabine |
1 |
13-sep-2026 |
conventional
|
| Tagraxofusp (CD123-directed post-HCT maintenance) |
1 |
13-sep-2026 |
conventional
|
| Revumenib (menin inhibitor) |
1 |
13-sep-2026 |
conventional
|
| Abemaciclib + Ruxolitinib combination |
1 |
13-sep-2026 |
conventional
|
| BEBT-507 |
1 |
13-sep-2026 |
conventional
|
| PXS-5505 (pan-LOX/LOXL inhibitor) |
1 |
13-sep-2026 |
conventional
|
| Azacitidine |
1 |
13-sep-2026 |
conventional
|
| UBP310/UBP296 (mGluR5 inhibitors) |
1 |
13-sep-2026 |
conventional
|
| Intensive 7+3 induction for secondary/blast-phase AML |
1 |
13-sep-2026 |
conventional
|
| Ferroptosis-based treatment strategies |
1 |
13-sep-2026 |
conventional
|
| Splenectomy for EMH-related complications in MF |
1 |
13-sep-2026 |
conventional
|
| Radiotherapy for extramedullary hematopoiesis in MF |
1 |
13-sep-2026 |
conventional
|
| Gecacitinib |
1 |
13-sep-2026 |
conventional
|
| Low-dose splenic irradiation (pretransplant MF) |
1 |
13-sep-2026 |
conventional
|
| Imetelstat (telomerase inhibitor) |
1 |
13-sep-2026 |
conventional
|
| Navtemadlin (MDM2 antagonist) |
1 |
13-sep-2026 |
conventional
|
| TP-3654 (PIM kinase inhibitor) |
1 |
13-sep-2026 |
conventional
|
| Mutant CALR-directed immunotherapy |
1 |
13-sep-2026 |
conventional
|
| Palliative hepatosplenic radiotherapy for EMH |
1 |
13-sep-2026 |
conventional
|
| Selinexor combination therapy in MDS/MPN overlap syndromes |
1 |
13-sep-2026 |
conventional
|
| Selinexor + Azacitidine combination |
1 |
13-sep-2026 |
conventional
|
| Aspirin (low-dose) |
1 |
13-sep-2026 |
conventional
|
| Low-molecular-weight heparin (LMWH) |
1 |
13-sep-2026 |
conventional
|
| Interferon-α (cytoreduction in MPN) |
1 |
13-sep-2026 |
conventional
|
| Low-dose aspirin |
1 |
13-sep-2026 |
conventional
|
| Interferon-α |
1 |
13-sep-2026 |
conventional
|
| Pharmacological C3 complement inhibition (myelofibrosis) |
1 |
13-sep-2026 |
conventional
|
| TPO/MPL pathway-targeted therapy |
1 |
13-sep-2026 |
conventional
|
| Anti-MPL neutralizing antibody |
1 |
13-sep-2026 |
conventional
|
| Aspirin (antiplatelet) |
1 |
09-aug-2026 |
conventional
|
| Imatinib |
1 |
09-aug-2026 |
conventional
|
| Pegylated interferon alfa-2a |
1 |
26-jul-2026 |
conventional
|
| Busulfan |
1 |
26-jul-2026 |
conventional
|
| iCasp9-transduced allodepleted T cells (CASPALLO) |
1 |
05-jul-2026 |
conventional
|
| Pacritinib + Venetoclax + Azacitidine combination (AP/BP MPN) |
1 |
05-jul-2026 |
conventional
investigational
|
| Ruxolitinib in Chronic Myelomonocytic Leukemia (CMML) |
1 |
05-jul-2026 |
conventional
investigational (off-label in CMML)
|
| FL118 (DDX5 protein degrader) |
1 |
05-jul-2026 |
conventional
|
| CD4CAR T-cell therapy (CD4-directed chimeric antigen receptor T cells) |
1 |
28-jun-2026 |
conventional
|
| Post-transplant HMA maintenance (oral decitabine/cedazuridine) |
1 |
28-jun-2026 |
conventional
|
| LY2784544 (JAK2 inhibitor) |
1 |
28-jun-2026 |
conventional
|
| Galectin-1 inhibition (novel therapeutic target in MPN) |
1 |
28-jun-2026 |
conventional
|
| Mutant CALR peptide vaccine (MPN immunotherapy) |
1 |
22-jun-2026 |
conventional
|
| Cytokine-induced memory-like (CIML) NK cells in myeloid malignancies |
1 |
22-jun-2026 |
conventional
|
| Ulixertinib + Ruxolitinib combination (ERK1/2 + JAK inhibition in myelofibrosis) |
1 |
21-jun-2026 |
conventional
|
| CIML NK cell therapy for post-transplant MPN relapse |
1 |
21-jun-2026 |
conventional
|
| E7820 (splicing factor inhibitor) |
1 |
21-jun-2026 |
conventional
|
| Imetelstat (telomerase inhibitor for MPN) |
1 |
21-jun-2026 |
conventional
|
| Conditioning regimen comparison: FluBu vs FluBu+TBI in myeloid malignancies |
1 |
21-jun-2026 |
conventional
|
| RAD001 (Everolimus, mTOR inhibitor) |
1 |
21-jun-2026 |
conventional
|
| Rusfertide (hepcidin mimetic for PV) |
1 |
21-jun-2026 |
conventional
|
| Recombinant EphB4-HSA fusion protein + HMA (azacitidine or decitabine) |
1 |
14-jun-2026 |
conventional
|
| Low-dose aspirin in Essential Thrombocythemia |
1 |
14-jun-2026 |
conventional
|
| Clopidogrel in Essential Thrombocythemia |
1 |
14-jun-2026 |
conventional
|
| Selinexor monotherapy (JAKi-refractory/intolerant myelofibrosis) |
1 |
14-jun-2026 |
conventional
|
| Elotuzumab (anti-SLAMF7 monoclonal antibody) in myelofibrosis |
1 |
14-jun-2026 |
conventional
|
| Cladribine + Low-dose Cytarabine + Venetoclax alternating with Azacitidine + Venetoclax (higher-risk CMML/MDS) |
1 |
07-jun-2026 |
conventional
|
| Eltrombopag (TET2-mutant low-risk MDS/CMML) |
1 |
07-jun-2026 |
conventional
|
| Selinexor monotherapy (cytoreduction in BCR::ABL1-negative MPN) |
1 |
07-jun-2026 |
conventional
|
| Rebecsinib (investigational agent for high-risk MF / sAML) |
1 |
07-jun-2026 |
conventional
|
| Hyperbaric Oxygen Therapy (peri-transplant) |
1 |
07-jun-2026 |
alternative
|
| Elritercept (MF anemia) |
1 |
07-jun-2026 |
conventional
|
| Sapablursen (TMPRSS6 antisense oligonucleotide) |
1 |
07-jun-2026 |
conventional
|
| BMS-986158 (BET bromodomain inhibitor) |
1 |
07-jun-2026 |
conventional
|
| Interferon-α mechanism of action in MPN |
1 |
07-jun-2026 |
conventional
|
| CD8-reduced T cells for MDS/AML in MPN progression |
1 |
31-may-2026 |
conventional
|
| CD24Fc (GVHD prevention in MPN transplant) |
1 |
31-may-2026 |
conventional
|
| Sosimerasib Sulfate Tablets (Jilemei) |
1 |
31-may-2026 |
conventional
NMPA conditional approval (priority review), February 2026
|
| Azacitidine ± Lenalidomide or Vorinostat (higher-risk MDS/CMML) |
1 |
31-may-2026 |
conventional
|
| Luspatercept (ACE-536) |
1 |
31-may-2026 |
conventional
|
| JBI-802 (investigational oral agent for MPN/MDS-MPN with thrombocytosis) |
1 |
31-may-2026 |
conventional
|
| PRT12396 (JAK2V617F mutant-selective JH2 inhibitor) |
1 |
24-may-2026 |
conventional
|
| CK0804 (investigational cell therapy for myelofibrosis) |
1 |
24-may-2026 |
conventional
|
| Olutasidenib + Hypomethylating Agent combination |
1 |
24-may-2026 |
conventional
|
| Venetoclax + Fludarabine/Busulfan conditioning + post-transplant maintenance |
1 |
24-may-2026 |
conventional
|
| TGR-1202 (PI3K-delta inhibitor) + Ruxolitinib combination |
1 |
24-may-2026 |
conventional
|
| Zavabresib (OPN-2853, selective BET inhibitor) |
1 |
17-may-2026 |
conventional
|
| PRT12396 (mutant-selective JAK2V617F inhibitor) |
1 |
17-may-2026 |
conventional
|
| Decitabine + FLAG-Ida + TBI conditioning regimen |
1 |
17-may-2026 |
conventional
|
| Thiotepa + Busulfan + Fludarabine (± ATG) conditioning regimen (CMML) |
1 |
17-may-2026 |
conventional
|
| TCR-based immunotherapy for MPN |
1 |
17-may-2026 |
conventional
|
| INCB000928 (investigational agent for MF-related anemia) |
1 |
17-may-2026 |
conventional
|
| Onvansertib (PLK1 inhibitor) for CMML/MDS-MPN overlap |
1 |
28-apr-2026 |
conventional
|
| Canakinumab (anti-IL-1β monoclonal antibody) for MDS/CMML |
1 |
28-apr-2026 |
conventional
|
| Guadecitabine + Atezolizumab combination |
1 |
28-apr-2026 |
conventional
|
| Accelerated/blast phase MPN pre-transplant bridging |
1 |
28-apr-2026 |
conventional
|
| NC525 (novel investigational agent for advanced myeloid neoplasms) |
1 |
28-apr-2026 |
conventional
|
| Azacitidine + Quizartinib combination |
1 |
28-apr-2026 |
conventional
|
| NMS-03592088 (novel investigational agent for AML/CMML) |
1 |
28-apr-2026 |
conventional
|
| Axatilimab (anti-CSF-1R antibody for advanced MPN/CMML) |
1 |
28-apr-2026 |
conventional
|
| Fludarabine + Busulfan + Low-dose TBI conditioning regimen |
1 |
28-apr-2026 |
conventional
|
| ASTX029 (ERK inhibitor) |
1 |
28-apr-2026 |
conventional
|
| CIML NK Cell Infusion + IL-2 (post-transplant relapse) |
1 |
28-apr-2026 |
conventional
|
| Seclidemstat + Azacitidine combination (MDS/CMML) |
1 |
28-apr-2026 |
conventional
|
| BGB-11417 (BCL-2 inhibitor for myeloid malignancies) |
1 |
28-apr-2026 |
conventional
|
| STX-0712 (novel investigational agent for CMML/AML) |
1 |
28-apr-2026 |
conventional
|
| Olutasidenib (IDH1 inhibitor, post-transplant maintenance) |
1 |
28-apr-2026 |
conventional
|
| JNJ-88549968 (novel investigational agent for CALR-mutated MPN) |
1 |
28-apr-2026 |
conventional
|
| Peginterferon alfa-2a (Pegasys) |
1 |
28-apr-2026 |
conventional
off-label in MPN (FDA-approved for hepatitis)
|
| Azacitidine + Venetoclax combination (higher-risk CMML) |
1 |
28-apr-2026 |
conventional
|
| CPX-351 (VYXEOS) for secondary myeloid neoplasms (pediatric/young adult) |
1 |
28-apr-2026 |
conventional
|
| Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis) |
1 |
28-apr-2026 |
conventional
|
| INCB160058 (novel investigational agent for MPN) |
1 |
28-apr-2026 |
conventional
|
| Ropeginterferon alfa-2b + Ruxolitinib combination (myelofibrosis) |
1 |
28-apr-2026 |
conventional
investigational
|
| MEX-CD1 extracorporeal iron chelation device |
1 |
28-apr-2026 |
conventional
|
| Selinexor monotherapy (JAKi-naïve myelofibrosis) |
1 |
28-apr-2026 |
conventional
|
| Nelfinavir (repurposed for myelofibrosis anemia) |
1 |
28-apr-2026 |
conventional
|
| Luspatercept (post-transplant erythroid engraftment) |
1 |
28-apr-2026 |
conventional
|
| WJ01024 + Ruxolitinib combination |
1 |
28-apr-2026 |
conventional
|
| Fedratinib + Nivolumab combination |
1 |
28-apr-2026 |
conventional
|
| Ruxolitinib + Ulixertinib combination |
1 |
28-apr-2026 |
conventional
|
| IOA-244 (PI3Kδ inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Flonoltinib Maleate (novel JAK inhibitor for myelofibrosis) |
1 |
28-apr-2026 |
conventional
|
| Nuvisertib (TP-3654) (PIM kinase inhibitor for myelofibrosis) |
1 |
28-apr-2026 |
conventional
|
| Ruxolitinib + Thalidomide combination |
1 |
28-apr-2026 |
conventional
|
| TQ05105 (novel JAK inhibitor for myelofibrosis) |
1 |
28-apr-2026 |
conventional
|
| CER-1236 (novel investigational agent for AML/MDS/MF) |
1 |
28-apr-2026 |
conventional
|
| STP938 (novel investigational agent for Essential Thrombocythemia) |
1 |
28-apr-2026 |
conventional
|
| INCA035784 (novel investigational agent for MPN) |
1 |
28-apr-2026 |
conventional
|
| INCA036978 (novel investigational agent for MPN) |
1 |
28-apr-2026 |
conventional
|
| Luspatercept |
1 |
28-apr-2026 |
conventional
|
| Ruxolitinib + Azacytidine combination |
1 |
28-apr-2026 |
conventional
|
| DISC-3405 (novel agent for Polycythemia Vera) |
1 |
28-apr-2026 |
conventional
|
| N-Acetylcysteine (NAC) for MPN |
1 |
28-apr-2026 |
alternative
|
| Ruxolitinib + Panobinostat combination |
1 |
28-apr-2026 |
conventional
|
| DISC-0974 (anemia-targeting agent for MF/MDS) |
1 |
28-apr-2026 |
conventional
|
| Flonoltinib Maleate (JAK inhibitor) |
1 |
28-apr-2026 |
conventional
|
| PMD-026 (RSK1 inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Direct Oral Anticoagulants (DOACs) for MPN thromboprophylaxis |
1 |
28-apr-2026 |
conventional
|
| Gecacitinib (JAK inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Curcumin (C3 complex/Bioperine) |
1 |
28-apr-2026 |
alternative
|
| Topotecan + Carboplatin + Veliparib |
1 |
28-apr-2026 |
conventional
|
| ZE74-0282 (novel JAK2 V617F-targeting agent) |
1 |
28-apr-2026 |
conventional
|
| Canakinumab (IL-1β monoclonal antibody) |
1 |
28-apr-2026 |
conventional
|
| PRT12396 |
1 |
28-apr-2026 |
conventional
|
| Selinexor + Pacritinib combination |
1 |
28-apr-2026 |
conventional
|
| Tasquinimod (S100A9/HDAC4 inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Givinostat (HDAC inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Sapablursen (TMPRSS6 inhibitor / hepcidin-axis RNA interference) |
1 |
28-apr-2026 |
conventional
|
| Iadademstat (LSD1 inhibitor) |
1 |
28-apr-2026 |
conventional
|
| Pemigatinib (Pemazyre) |
1 |
28-apr-2026 |
conventional
|
| Allogeneic stem cell transplant |
1 |
28-apr-2026 |
conventional
|
| Traditional Chinese Medicine (general) |
1 |
28-apr-2026 |
conventional
|
| SLAMF7 immunotherapy |
1 |
28-apr-2026 |
conventional
|
| CAR-T therapy for myelofibrosis |
1 |
28-apr-2026 |
conventional
|
| Pelabresib |
1 |
28-apr-2026 |
conventional
|
| CK0804 (Allogeneic Regulatory T-cell Therapy) |
1 |
28-apr-2026 |
conventional
|
| Roginolisib + Ruxolitinib combination |
1 |
28-apr-2026 |
conventional
|
| Curcumin (turmeric) |
0 |
28-apr-2026 |
alternative
investigational
|
| Omega-3 fatty acids |
0 |
28-apr-2026 |
alternative
investigational
|